Percutaneous Native Kidney Biopsy Complications in Diabetic Patients in the TRIDENT Cohort.

Authors

Samer Mohandes, Mohammad Fakhreddine, Henry Sheng, Mohammed Al Dulaimee, Amy Mottl, Julia Scialla, Salem Almaani, Randy Luciano, Tamara Isakova, Shweta Bansal, Christos Argyropoulos, Rupali Avasare, Manisha Singh, Kirk N Campbell, Raymond Townsend, Gaia Coppock, Matthew Palmer, Katalin Susztak, TRIDENT Consortium

Published in

Clinical journal of the American Society of Nephrology : CJASN. Jun 15, 2026. Epub Jun 15, 2026.

Abstract

Percutaneous kidney biopsy is essential for diagnosing kidney disease but carries a risk of bleeding and other complications. Reported complication rates vary widely because of heterogeneity in outcome definitions. Patients with diabetes frequently have hypertension, vascular stiffness, and altered hemostasis, which may further influence biopsy safety. The multicenter Transformative Research in Diabetic Nephropathy (TRIDENT) study prospectively evaluated biopsy complications in adults with diabetes using standardized definitions across 21 sites from the United States.
We analyzed 408 native kidney biopsies from participants with diabetes enrolled in TRIDENT (2017-2025). Complications were classified as minor (hematoma, biopsy site pain, or hemoglobin (Hb) drop), resource-intense (transfusion, radiologic or surgical intervention, or prolonged hospitalization), and major bleeding (≥2 grams/deciliter (g/dL) Hb decline, transfusion, or intervention). Logistic regression with site clustered robust errors was used to identify clinical and procedural associations with outcomes.
Among 408 biopsies, 81 complications (20%) occurred, most commonly hematoma (15%); resource-intense events were infrequent (5%). Use of an 18-gauge (vs 16-gauge) needle was associated with lower odds of resource intense events (odds ratio (OR) 0.32; 95% confidence interval (CI) 0.17-0.60). Procedures by fellows, hybrid teams, or interventional radiologists had higher odds than those by attendings (OR 3.12-13.4). Renin-angiotensin system inhibitors (RAASi) use was independently associated with lower odds (OR 0.13; 95% CI 0.02-0.73). Female sex (OR 4.88; 95% CI 1.02-45.3)and post-biopsy hematoma (OR 14.3; 95% CI 3.66-74.5) were associated with major bleeding, whereas the number of passes correlated with hematoma formation but not with adjusted major bleeding risk.
In adults with diabetes, clinically significant biopsy complications were uncommon and were associated with procedural and operator factors rather than diabetes. Smaller gauge needles and experienced operators were associated with lower risk, whereas female sex and hematoma were associated with major bleeding. The higher overall complication rate mainly reflected comprehensive, prospective ascertainment of minor events, and supports standardized definitions and procedures to improve biopsy safety in diabetic kidney disease.

PMID:
42295857
Bibliographic data and abstract were imported from PubMed on 15 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.